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ABSTRACT
BACKGROUND AND OBJECTIVES
Coronary artery disease is the important cause of mortality and morbidity in the 
world as well in India. 
Transient decrease in serum potassium during episode of acute coronary syndrome 
is thought to be a common finding, but so far there are not many studies 
demonstrating it occurrence in ACS and its significance. Delta potassium defined 
as the difference between potassium during the time of discharge and on admission 
[k-k at the time of discharge- k at the time of admission] reflect potassium drop 
during acute coronary syndrome and it has been thought to be associated with the 
disease severity in patient with ACS. 
Apart from well-known factors influencing mortality and morbidity in patient with 
acute coronary syndrome like female sex, associated co morbid illness like 
diabetes mellitus[DM], Systemic hypertension[SHT], dyslipidaemia, age ,
smoking, alcoholism, delta potassium has also thought to be associated with 
disease severity and influence the course of the disease in patients with ACS.
The present study is an attempt to study its prevalence and its significance in 
patient of acute coronary syndrome group. 
METHODS AND MATERIALS:
STUDY DESIGN: CROSS SECTIONAL STUDY.
STUDY GROUP: Patients with acute coronary syndrome
1] STEMI 2] UNSTABLE ANGINA 3] NSTEMI 
MATERIALS: Detailed history, Physical examination, ECG, 2D 
Echocardiography, Chest x-ray, Complete Haemogram, Rbs, Blood urea, Serum 
Creatinine, Serum potassium, cardiac enzyme CPK-MB, Urine Routine, Total 
Cholesterol, Triglyceride levels.
PLACE OF STUDY: Govt. Kilpauk medical college hospital
DURATION OF STUDY: 6 months
METHODOLOGY:1)Potassium dip will be assessed by Δk-potassium at the time 
of discharge – potassium at the time of admission. 
2) Severity of ACS assessed by
a) Duration of hospital stay b) 2D echo c) Cardiac enzyme CPK-MB assay.
INCLUSION CRITERIA: 
All patients > 35 yrs of age admitted with 1st episode of acute coronary syndrome, 
EXCLUSION CRITERIA:
1] Previous history of CAD. 2] Patients with CKD. 3] Patients on potassium 
controlling agents like ACE inhibitors, diuretics etc.
RESULTS
A] Among 65 patients with STEMI 47 had delta potassium value more than 0.5 
which constitute 72%. In patients with NSTEMI 66% has significant delta 
potassium. But in UNSTABLE ANGINA group only 23% has delta potassium 
more than 0.5.
B] Delta potassium has also shown to be positively correlated with duration of stay 
in hospital as shown below. 
1] Patient who stayed for 5 or less- 19% has significant delta potassium
2] In the patient who stayed for 5 to 7- 76% has delta potassium more than 0.5
3] In patients who stayed for more than 7 days- 96% has significant delta k.
  
C] The relationship between delta potassium and LV dysfunction also correlate 
positively. In 17 patients with normal only 2 has delta potassium more than 2. In 
patients with mild LV dysfunction 33% has significant delta potassium. But 92% 
of patients with moderate and 93% of patients with severe LV dysfunction has 
delta potassium more than 0.5.
CONCLUSION
1] Prevalence of potassium dip is common among patients with acute coronary 
syndrome. 
2] Diabetic patients does not have significant delta potassium. 
3] Low potassium value at the time of admission [less than 4] was not found to 
correlate with disease severity in this study.
4] Delta potassium was positively correlated with severity of ischemic stress in 
patients with ACS.
5] Age, sex, diabetes, SHT, dyslipidaemia, smoking and alcoholism do not have 
major impact on delta potassium.
KEY WORDS 
1] Delta potassium 2] acute coronary syndrome 3] severity of ischemic stress 4] 
duration of stay5] left ventricular dysfunction. 
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INTRODUCTION 
 
Coronary artery disease is the important cause of mortality and morbidity in the 
world as well in India. Patient with ischemic heart disease falls in to two major 
group- stable angina and acute coronary syndrome[ACS]. Patient with acute 
coronary syndrome falls into three major group 1] patient with ST elevation 
myocardial infarction (STEMI), 2] NSTEMI(non ST elevation MI), 3] unstable 
angina. The prevalence of risk factors as well as IHD is increasing in 
developing countries like India.   
 Transient decrease in serum potassium during episode of acute coronary 
syndrome is thought to be a common finding, but so far there are not many 
studies demonstrating it occurrence in ACS and its significance. Delta 
potassium defined as the difference between potassium during the time of 
discharge and on admission [k-k at the time of discharge- k at the time of 
admission] reflect potassium drop during acute coronary syndrome and it has 
been thought to be associated with the disease severity in patient with ACS.  
Apart from well-known factors influencing mortality and morbidity in patient 
with acute coronary syndrome like female sex, associated co morbid illness like 
diabetes mellitus[DM], Systemic hypertension[SHT], dyslipidaemia, age , 
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smoking, alcoholism, delta potassium has also thought to be associated with 
disease severity and influence the course of the disease in patients with ACS. 
The present study is an attempt to study its prevalence and its significance in 
patient of acute coronary syndrome group.  
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AIM OF THE STUDY: 
 
1) To study the prevalence of delta potassium in patient with acute coronary 
syndrome. 
2) To study the distribution of delta potassium in various group of patient in 
acute coronary syndrome. 
3) To study the correlation between delta potassium and disease severity in 
patients with acute coronary syndrome.        
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REVIEW OF LITEREATURE 
EPIDEMIOLOGY OF CHDIN INDIA: 
Coronary heart disease is emerging as the leading cause of death in India and 
also worldwide.  Previously it was thought to be prevalent primarily in 
developed countries but it now leads to more death and morbidity in low and 
middle-income countries [ex: India] and rates are increasing disproportionately 
when compared to developed countries. It affects young people in low- and 
middle-income countries, when compared to high-income countries. Thus it has 
a greater impact on economic development in low- and middle-income 
countries 
[1]
.  
PREVALENCE OF CHD INDIA [2007 ESTIMATES] 
FIG: 1 SHOWING URBAN PREVALENCE OF CHD. 
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FIG:1. 2 SHOWING RURAL PREVALENCE OF CHD 
 
TABLE 1 SHOWING BURDEN OF CHD IN WORLD AND INDIA 
 
The above table is a comparison between India and world burden of coronary 
artery disease. 
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ACUTE CORONARY SYNDROME:   
Three groups of patients are included in acute coronary syndrome  
1) STEMI  
2) NSTEMI 
3) UNSTABLE ANGINA.  
 UA is diagnosed when patient have chest pain or other similar symptoms or 
least any of the following one features: 
 (1) It comes even during rest (or only with minimal exercise) and last for 
prolonged period usually >10 minutes.                                  
(2) Pain becomes severe and of recent onset (i.e., last four to six weeks). 
(3) The pain increases in ascending pattern (i.e.it becomes more severe, last 
longer, occur more frequently than previously).  
NSTEMI is diagnosed if the patient has the clinical features of unstable angina  
and evidence of myocardial necrosis, as evidenced by elevated cardiac enzymes. 
STEMI is diagnosed when patient with typical angina pain has ST elevation in 
12 lead ECG and raised cardiac biomarkers. 
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ATHEROSCLEROSIS 
Atherosclerosis is characterized by the presence of intimal lesions called as 
atheroma’s[also called atherosclerotic plaques] which protrude into affected 
vessel lumen
[2]
. The atheromatous plaque consists of a raised lesion with 
soft,yellow core which consist of lipid (mainly cholesterol and cholesterol 
esters) and covered by a firm, white fibrous cap. This cause obstruction to blood 
flow, and also weaken the underlying media and when it ruptures, causes acute 
catastrophic vessel thrombosis. 
TABLE.2.RISK FACTORS FOR ATHEROSCLEROSIS 
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NON MODIFIABLE RISK FACTORS 
Age 
Age has a dominant influence in atherosclerosis pathogenesis. Though the 
accumulation of atherosclerotic plaque is a progressive process, it does not 
clinically manifest until lesions reach a critical threshold. Then it begins to 
cause organ injury in middle age or later. Thus, in fourth to sixth decades of 
ages, the incidence of myocardial infarction in men increases by five times 
[3]
 
even though the underlying arterial lesions were evolving before that.  
Gender 
Premenopausal women are protected against atherosclerosis and all its 
complications if compared to men of same ages. This explains why myocardial 
infarction and other complications of atherosclerosis are uncommon in 
premenopausal women unless they have other risk factors for MI like diabetes, 
hyperlipidemia, or systemic hypertension 
[4]
. However, after menopausal age, 
the incidence of atherosclerosis-related diseases begins to increases and with 
advanced age eventually becomes more than that of men. This is explained by 
favourable influence of oestrogen on this process.  
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GENETICS 
The familial tendency to atherosclerosis and its complication Ischemic heart 
disease is a well-known fact and it is influenced by several factors. In some 
instances it is due to presence of other risk factors, such as systemic 
hypertension or diabetes in the same family whereas in others it involves well-
defined genetic derangements in lipid metabolism, such as familial 
hypercholesterolemia, that result in excessively high blood lipid levels 
[5]
. 
 
MODIFIABLE RISK FACTORS 
 
Hyperlipidemia 
It is a well-known major risk factor for atherosclerosis; even in the absence of 
other risk factors, hypercholesterolemia by itself can cause lesion development. 
The most important serum lipid component associated with coronary heart 
disease is low-density lipoprotein (LDL) cholesterol 
[6]
.LDL cholesterol major 
function is to deliver cholesterol to peripheral tissues. In contrast, high-density 
lipoprotein [HDL] mobilizes cholesterol from atheromas and transports it to the 
liver after which is excreted into the bile 
[7]
. Hence higher levels of serum HDL 
is associated with reduced risk. 
Diet and pharmacologic approaches which lower LDL or total serum 
cholesterol, and raise serum HDL are all of considerable interest. High dietary 
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intake of egg, animal fats and butter raises plasma cholesterol levels. On the 
other hand intake of diets low in cholesterol and with higher ratios of 
polyunsaturated fatty acids lowers plasma cholesterol levels. Omega-3 fatty 
acids (rich in fish oils) are beneficial, whereas unsaturated fats which are 
produced by hydrogenation of polyunsaturated oils (present in baked foods and 
margarine) negatively affect cholesterol profiles. Regular exercise and moderate 
intake of alcohol raise HDL levels, whereas obesity and smoking decreases it.  
HYPERTENSION 
Hypertension is another major important risk factor which is associated 
atherosclerosis; systolic and diastolic blood pressures are equally important. 
Ischemic heart disease risk increases by approximately60% in hypertensive 
patients when compared to populations with normal blood pressure 
[8]
. When 
hypertensive patient is not treated approximately half of patients will die of IHD 
or congestive heart failure, and another third will die with the development of 
stroke. 
CIGARETTE SMOKING 
Cigarette smoking is associated with increased risk in men, and women. 
Chronic daily smoking of more than one pack of cigarettes increases the death 
rate from IHD by 200%. When it is stopped the risk is reduced markedly 
DIABETES MELLITUS 
Diabetes aggravates dyslipidaemia and atherosclerosis occurs more frequently. 
The risk of acquiring MI is twice in diabetes as compared to non-diabetes. 
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PATHOGENESIS 
The atherosclerosis is a chronic inflammatory process of the arterial wall which 
occurs following endothelial injury 
[9]
.Lipoproteins, lymphocytes, macrophages 
and the normal cellular constituents of the arterial wall all interacts and it lead to 
the progression of the atherosclerosis lesion. The proposed hypothesis is 
endothelial dysfunction results from chronic endothelial injury and result in 
high permeability, leukocyte adhesion, and   accumulation of lipoproteins 
(mainly LDL and its oxidized forms) in the vessel wall, after adhesion to the 
endothelium monocytes migrates into the intima and it is converted into 
macrophages and foam cells 
[10]
. Platelet adhesion Factor gets released   from 
activated platelets, and vascular wall cells and it induces SMC recruitment, 
either from the tunica media or from circulating precursors.  Lipid accumulation 
occurs both outside the cells and intracellularly. 
FIGURE 1.3 SHOWING ATHEROMA COMPONENTS 
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CORONARY ATHEROSCLEROSIS: 
Atherosclerotic disease occurs mainly in large vessel like epicardial coronary 
artery. The important factors associated with atherosclerosis (increased plasma 
LDL , decreased serum high-density lipoprotein , chronic smoking, 
hypertension, and DM) interferes with the normal functions of the vascular 
endothelium which include control of local vessel tone, maintaining 
antithrombotic surface, and control of inflammatory cell adhesion and 
diapedesis. When these properties are lost it results in pathologic constriction, 
thrombus formation, and abnormal interactions among blood cells, most 
importantly between macrophages and platelets and the activated vascular 
endothelial cells. These functional changes lead to the subintimal collections of 
lipids, smooth muscle cells, fibroblasts, and intercellular matrix that result in the 
atheroma formation. There is a tendency for atherosclerotic plaques to form at 
sites where increased turbulent coronary flow occurs, commonly at branch 
points in the epicardial arteries. When vascular stenosis reduces the diameter of 
an epicardial artery by 50%, ability to increase coronary flow is limited when 
myocardial demand is increased. When the diameter is reduced by 
approximately 80%, blood flow may be reduced even during period of rest, and 
further small decreases in the stenotic orifice area can decrease coronary flow 
markedly and cause myocardial ischemia at rest or only with minimal stress 
[11]
. 
19 
 
 Narrowing of epicardial coronary artery by atherosclerosis in most of case is 
caused by the formation of a plaque, which can leads to rupture or erosion of the 
cap and this separates plaque from the bloodstream. When plaque contents is 
exposed two important and related processes occurs: (a) platelets activation and 
aggregation, and (b) the coagulation process is activated, which results in 
deposition of fibrin strands 
[12].
 The thrombus consist mainly platelet aggregates 
and fibrin strands along with red blood cells and it can reduce coronary blood 
flow, resulting in the clinical manifestations of myocardial ischemia. 
The location of the thrombus determines the quantity of myocardial cells 
becoming ischemic and determines the severity of the clinical features. Thus, 
critical obstructions narrowing diameter of coronary vessels, such as the left 
main coronary artery and the proximal portion left anterior descending coronary 
artery, are associated with poor outcome. Chronic severe coronary vessel 
narrowing and myocardial ischemia ultimately result in the development of 
collateral blood vessels, particularly when the narrowing develops gradually. 
When well developed, such collateral vessels alone can provide sufficient blood 
flow and sustain the viability of the myocardial cells at rest but not during time 
of increased demand 
[13-16]
. 
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PATHOPHYSIOLOGY 
UA/NSTEMI is caused by a reduction in oxygen supply or by an increase in 
myocardial oxygen demand which is superimposed on a lesion that causes 
coronary arterial obstruction, usually an athero thrombotic coronary plaque. 
Pathophysiologic processes that are involved in the development of 
UA/NSTEMI can be explained as follows 
[17-20]
: 
(a) Plaque rupture or erosion which leads to formation of superimposed non 
occlusive thrombus in such patients, NSTEMI will occur when platelet 
aggregates and/or atherosclerotic debris embolise to vessels which are further 
down. 
 (b) Transient vessel wall narrowing [e.g., coronary vasospasm in Prinzmetal 
angina] 
(c) Progressive occlusion of vessel (e.g., rapidly developing coronary 
atherosclerosis or stenosis of coronary vessel after coronary intervention) 
(d) UA in due to increased myocardial oxygen requirements and decreased 
blood supply. 
More than one of the above said process may be involved in the same patient. 
 5% of the patients with unstable angina or non ST elevation MI when studied 
angiographically have stenosis of the left main coronary artery, fifteen percent 
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of patients have triple vessel CAD, thirty percent have disease in two coronary 
vessel, forty percent disease in one coronary artery, and ten percent have no 
significant epicardial coronary vessel stenosis, in this group the pain may be due 
to obstruction in coronary microcirculation. Narrow neck and stenosis in the 
eccentric region are the angiographic finding of the pathologic atheromas lesion 
[ 21-22]
. 
Angioscopy has been reported to show "white" thrombus, which is rich in 
platelet in contrast to "red" thrombus which is rich in fibrin and cells; the latter 
are very often seen in patients with acute ST elevation myocardial infarction. 
Most of these patients with UA/NSTEMI have multiple plaques which are at 
risk of disruption and are called as vulnerable plaques. 
FIG 1.4PROCESS OF THROMBUS FORMATION INVOLVING 
PLATELET ADHESION, ACTIVATION AND   AGGREGATION 
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CLINICAL PRESENTATION 
History and clinical features 
 pain in the left retrosternal or discomfort in the epigastric region are the most 
common presenting feature in patient with acute coronary syndrome, and 
frequently radiates to the region of neck, left shoulder but more commonly to 
the left arm. This discomfort is usually very severe and may be experienced as 
frank pain 
[23]
. 
―Anginal equivalents" are features other than chest pain in patients with CAD 
such as breathlessness and discomfort in epigastric region may also occur, and 
these occurs frequently in females 
[24]
.The physical examination is similar to 
that seen in patients with stable angina and sometimes not well prominent. If the 
patient is affected by severe myocardial ischemia or extensive NSTEMI, the 
clinical features like increased sweating, pale and cool peripheries, increased 
heart rate, gallop rhythm, pulmonary creps and shock, similar to the features 
seen in patients with STEMI can be seen 
[25]
. 
Evaluation of patients with suspected unstable angina/NSTEMI should include 
the expert opinion of whether the chest discomfort likelihood of being caused 
by 
[26]
 myocardial ischemia can be in one of three categories: high, intermediate, 
or low.  
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TABLE 3: SHOWS PROBABLITY OF CHEST PAIN BEING ANGINA. 
 
ELECTROCARDIOGRAM 
In unstable angina, ST-segment depression, temporary elevation of ST segment, 
and inversion of T wave is seen in up to thirty to fifty percent of patients. In 
patients with the symptoms and signs of unstable angina, occurrence of new ST 
segment changes, as small as 0.05 mill volt, is an important finding and it is 
associated with poor prognosis. ECG changes in T-wave are sensitive for 
myocardial ischemia but are specific, only when they are new, deeper and 
magnitude of T wave inversions is 0.3millivolt. 
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CARDIAC BIOMARKERS 
Patients who has unstable angina/NSTEMI and have elevated cardiac enzymes 
indicating death of the myocardium, such as Troponin and CPK-MB [this is a 
specific and sensitive indicator of myocardial cell necrosis], and are at increased 
risk for death or recurrent MI. When levels of these cardiac bio markers 
increase it helps to differentiate patients with NSTEMI and UA. 
There is a positive correlation between the level of troponin increase and death 
rate. However minor elevations in troponins have been seen in patients without 
myocardial ischemia and is be due to congestive cardiac failure, myocarditis, or 
systemic embolism, or it may be false positive feature. Thus, in patients without 
clear history, mild elevations in troponin cannot be used for diagnosis of 
myocardial ischemia. 
ST ELEVATION MYOCARDIAL INFARCTION 
Chest Pain is the most common presenting feature seen in patients with ST 
elevation MI. The location of pain is deep and visceral patient commonly 
describes it as squeezing and crushing but uncommonly it is described as 
stabbing or burning in nature. It is similar in character to the pain occurring in 
angina pectoris but the differentiating feature is it occurs at rest, is usually more 
severe, and duration is longer. 
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FIG: 1.5 ALGORITHMS FOR RISK STRATIFICATION AND 
MANAGEMENT OF PATIENTS WITH SUSPECTED ISCHEMIC 
HEART DISEASE
 
 
Typically the pain is localized to the centre of the chest and/or the epigastrium, 
and, on occasion, it may present as radiating pain to the arms. Less commonly it 
also radiates to abdomen, neck, back, lower jaw and the most common location 
of the pain is beneath the xiphoid and epigastrium. The pain of STEMI may 
radiate as high as the occipital area but never present as pain below the level of 
umbilicus.  It is commonly associated with diaphoresis, nausea, vomiting, 
anxiety, and a sense of impending doom.   
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FIG: 1.6 TIMIRISK SCORE FOR UNSTABLE ANGINA/ NSTEMI 
 
ON EXAMINATION 
Patients with MI appear anxious and are uncomfortable. Those with marked left 
ventricular (LV) failure at the time of presentation may have 
1. Tachycardia, 
2. Pulmonary creps,  
3. Tachypnea,  
4. Third heart sound.  
 Mitral regurgitant murmur when presents it suggests dysfunction of the mitral 
valve apparatus due to ischemia, rupture of chordae tendinae, or ventricular 
remodelling 
[27]
. 
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 Patients with infarction of the right ventricle, have raised jugular venous 
pressure, Kussmaul sign (increase in JVP with inspiration),and a third heart 
sound due to right ventricular dysfunction may be present. Such patients usually 
have associated inferior infarctions, usually without evidence of left-heart 
failure. 
ELECTROCARDIOGRAM 
In a patient having active chest pain, the following features when present 
STEMI can be diagnosed 
[28-29]
. 
A]. ST-segment elevation ≥ 1 mm (0.1 mV) in two or more adjacent limb leads 
(from aVLto III, including -aVR),  
B]. ST-segment elevation ≥ 1 mm (0.1 mV) in chest leads V4 through V6,  
C]. ST-segment elevation ≥ 2 mm (0.2 mV) in chest leads V1 through V3, ].  
D].New left bundle-branch block.  
Myocardial infarction evolves through three phase and its characteristics ECG 
findings are as follows.  
1.   The hyperacute  phase 
A]. Increased R wave amplitude.  
B]. Increased ventricular activation time 
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C].Tall and widened T wave  
 D]. Slope ST Segment elevation.  
 
2.    The fully evolved phase;  
A]. QS or QR complex, loss of R wave amplitude  
B]. Coved ST segment elevation.  
 C] .Symmetrical pointed T wave inversion.  
3.    The chronic stabilised phase  
A]. Prominent Q waves.  
B]. Isoelectric ST segment.  
C].Upright T wave. 
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BIOMARKERS USED IN MI 
Relative index which is the ratio of CKMB mass: CK activity -2.5 suggests of a 
myocardial source for the CKMB elevation. 
FIG: 1.7 CARDIAC BIOMARKERS CHARACTERSTICS FEATURES 
 
ECHOCARDIOGRAM 
Areas of abnormal regional wall motion are observed virtually in all patients 
with MI, and the degree of wall motion abnormality can be categorized with a 
semi quantitative wall motion score index, abnormal wall motion is less often 
noted echocardiographically when the infarction involve small area and the age 
of regional wall motion abnormality cannot  be determined. Left ventricular 
function can be estimated from 2D echo and is useful in establishing prognosis 
after myocardial infarction. 
The early use of echocardiography can be used in the early detection of 
potentially viable but stunned myocardium (contractile reserve),  patients at risk 
for the development of congestive heart failure following MI, and mechanical 
complications. 
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DIAGNOSIS 
STEMI is diagnosed if patient has any two of the following. 
A].Patient with ischemic discomfort 
B]. ST elevation in electrocardiogram  
C]. Rise in serum biomarker. 
TABLE:4 KILLIP’SCLASSIFICATION OF PATIENTS WITH ACUTE 
MI. 
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TABLE:5 LOCALISATION OF MI AND ITS SPECIFIC 
COMPLICATION 
 
DIFFERENTIAL DIAGNOSIS 
For patients having acute chest pain, consider the following diagnoses:  
• Aortic Dissection  
• Pneumothorax 
• Pulmonary embolism 
• Myocarditis 
• Pericarditis 
• Oesophageal rupture or spasm 
• Hypertensive urgency or emergency 
• GERD 
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• Intercostal muscle strain 
• Costochondritis 
 
TREATMENT 
Nitrates are administered by sublingual route or it is given by oral spray (0.3–
0.6 mg) in patient experiencing ischemic pain. If patient have pain even after 
giving 3 doses, intravenous NTG [5–10 microgram/min] should be given. The 
rate of the infusion may be adjusted by increasing 10 microgram/min every 
three to five minutes till symptoms subsides or systolic blood pressure becomes 
less than 100 mmHg. 
Hypotension and simultaneous intake of sildenafil group drugs in the previous 
one or two days are the important contraindication and nitrates are avoided in 
them. 
ANTITHROMBOTIC AGENTS 
Oral antiplatelet therapy 
This forms the main component in the treatment of patients with unstable 
angina/NSTEMI. Initial treatment should include the administration of platelet 
COX inhibitor aspirin 
[30]
.The common starting dose is 325 mg/d, Low doses 
(75–160 mg/d) is given for long-term therapy. "Aspirin resistance" occurs in 
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five to ten percent of patients. Treatment with lower dose and non compliance 
to treatment are the reason suspected for this phenomenon. 
 The clopidogrel an inactive prodrug that is converted into an active metabolite, 
then it act by blocking the platelet ADP receptor, when used in combination 
with aspirin,it  was shown to provide  a twenty percent relative reduction  death 
due cardiovascular events, MI, or stroke, compared with aspirin alone. This 
effect is seen in both low and high risk patients. Disadvantage of this 
combination is a moderate but absolute one percent increase in significant 
bleeding episode 
[31]
. 
Pre-treatment with clopidogrel [300 or 600 mg loading dose, followed by 75 mg 
OD] is given prior to PCI. 
The combination of clopidogrel and aspirin treatment for one year has been 
shown to benefit patient treated conservatively and PCI 
[32]
. 
HEPARIN 
The various options for anticoagulant therapy to be combined with aspirin and 
clopidogrel are as follows. Conventional heparin is the important mode of 
treatment. The low-molecular weight heparin, enoxaparin, is superior to UFH 
and it reduces further cardiac events, mainly in conservatively treated 
patients
[33]
. The fondaparinux, an indirect factor Xa inhibitoris same efficacy 
when compared with enoxaparin and it has the advantage of lower risk of major 
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bleeding. Bivalirudin, a direct thrombin inhibitor, also equal potency to either 
UFH or LMWH but when  bivalirudin alone is used it has less bleeding when 
compared to the combination of heparin and a GP IIb/IIIa antagonist in patients 
with Unstable angina and non ST elevation MI undergoing catheterization 
and/or PCI 
[34]
. 
TABLE:6 CLINICAL USE OF ANTITHROMBOTIC AGENTS. 
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BETA BLOCKERS AND OTHER AGENTS 
Beta blockers are the other main components of anti-ischemic treatment. Oral 
beta blocker titrated to achieve heart rate of 50–60 beats/min is the used as first-
line treatment 
[35]
. 
  Intravenous beta blocker is used judiciously in patients with any evidence of 
acute heart failure, where it can increase the risk of cardiogenic shock. Drugs 
like diltiazem and others in calcium channel blockers group which act by 
decreasing heart rate are used in patients whose symptoms are not relieved 
despite treatment with maximum dose of nitrates and beta blockers and in 
patient whom beta blocker cannot be used due to contraindications. Other 
modes of therapy include ACE inhibitors and HMG-CoA reductase inhibitors –
statins for long term secondary prevention of IHD 
[36]
. Early intensive statin 
therapy (e.g., atorvastatin 80 mg) prior to percutaneous coronary intervention 
(PCI) has been shown to reduce complications hence high-dose statin therapy 
should be started at the time of admission. 
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TABLE:7 SUMMARIES OF DRUGS USED IN ACS 
 
The above table shows various group of drugs used in ACS, their indication, 
dose and adverse effects. 
 
 
 
37 
 
INVASIVE THERAPY 
Early invasive therapy is given to patients with high risk,that is in patients 
having multiple clinical risk factors, ST-segment changes, and raised 
biomarkers.  In this mode of therapy, following treatment with anti-ischemic 
and antithrombotic agents, coronary angiography is done within forty eight 
hours of admission 
[37-39]
, followed by coronary intervention procedure [PCI or 
coronary artery bypass grafting], depending on anatomy of coronary vessel. 
TABLE:8 INDICATIONS FOR EARLY INVASIVE THERAPY IN ACS. 
 
STEMI MANAGEMENT 
 The main goal of treating patient with STEMI should be rapid reperfusion to 
re-establish blood flow to ischemic myocardium. There are three main 
reperfusion strategies in practice currently 
[40]
: 
 1] Thrombolytic therapy, 
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 2] Primary PCI, and  
 3] Thrombolytic-facilitated primary PCI.   
THROMBOLYTIC THERAPY 
It is an effective therapy in STEMI and should be given within 3 hrs of onset of 
chest pain for its maximal effect 
[41]
. 
Class I 
1. In the absence of contraindications, fibrinolytic drug can be given to 
STEMI patients with symptom onset within the previous 12 hours and has ST 
elevation greater than 0.1 mV in at least two contiguous chest leads or at least 
two adjacent limb leads
[42]
. (Level of Evidence: A) 
2. Fibrinolytic therapy is also indicated in STEMI patients with symptom onset 
within the prior 12 hours and new or presumably new onset LBBB. (Level of 
Evidence: A)   
Class IIa 
1. When there is no contraindication it is reasonable to administer fibrinolytic 
therapy to STEMI patients with symptom onset within the prior 12 hours and 
ECG finding shows  true posterior MI. [Level of Evidence: C] 
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2. When there is no contraindications, it is justifiable to use fibrinolytic therapy 
to patients who has symptoms of STEMI beginning within the previous twelve 
to twenty four hours who have persistent ischemic symptoms and ST elevation 
greater than 0.1 millivolt in at least two continuous chest leads or in  two 
adjacent limb leads. [Level of Evidence: B] 
Class III 
1. Fibrinolytic therapy is not used in asymptomatic patients whose symptoms of  
STEMI started more than 24 hours earlier. [Level of Evidence: C] 
2. Fibrinolytic therapy is not used in patients whose ECG shows only ST-
segment depression except if a posterior wall MI is suspected. [Level of 
Evidence;A] 
TABLE: 9.CONTRAINDICATION OF THROMBOLYTIC AGENTS 
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TABLE: 10 FIBRIN SPECIFIC THROMBOLYTIC AGENTS 
 
PRIMARY PCI 
 95 percent of patients treated with primary PCI obtain complete perfusion 
where-as only 50 to 60 percent of patients has complete reperfusion when 
treated by thrombolysis 
[43]
. Primary PCI has also advantage of lower risk of 
stroke and angiography quickly defines coronary anatomy, left ventricular (LV) 
function, and mechanical complications following MI.  
THROMBOLYTICS FACILITATED PCI 
It refers to the pre-treatment with thrombolytic in STEMI patients before PCI 
and it act as a bridge therapy to immediate PCI. Currently it is not 
recommended as first line therapy 
[44-45]
. 
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FIG: 1.8 ALGORITHMS FOR MANAGEMENT OF STEMI 
 
 
The above algorithm shows if facilities are available PCI is the preferred mode 
of intervention in STEMI patients. If not possible thrombolysis can be used. 
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POTASSIUM AND ACUTE CORONARY SYNDROME 
Acute coronary syndromes provide a useful clinical model for understanding of 
sympathetic stress as evidenced by number of classical symptoms such as 
excessive sweating and tachycardia. Hypokalaemia has been thought to be due 
to this mechanism.  
Hypokalaemia can be considered as an acute phase response to sympathetic 
[46]
, 
Activation which occurs following myocardial ischemia and this subsequently 
activates sodium potassium- ATPase enzyme which is present on the cell 
membrane bound and shift potassium intracellularly. 
ΔK = K at discharge - K on admission.    
There are number of factors modifying the extent of the potassium dip (as 
indicated by ΔK) and serum glucose concentration during the period of 
ischemia was the only factor which was positively correlated with ΔK. On the 
other hand, HbA1c level was found to be inversely related with delta potassium 
[47].There was no relation between the intake of drug and ΔK [48].. The use of 
ACE-inhibitors, AR is not associated with change in delta potassium.   
The other mechanism responsible for hypokalaemia in ACS is reactive increase 
in insulin 
[49]
 which occurs in response to adrenergic drive secondary to 
increases in serum glucose. This insulin in turn stimulates an intracellular shift 
of potassium into the cardiac and skeletal muscles by activating 
Na+/K+ATPase, which leads to the decrease in serum K level.   
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Raised blood glucose level during period of ischemia is strongly correlated with 
an high delta potassium
[50]
and it does not associate with of the severity of 
diabetes. These findings show that resistant to insulin may have a role in 
decreasing the potassium dip and that there is another serum potassium 
decreasing systems that may counteract the effects of insulin resistance 
[51]
. 
The systemic sympathetic system is activated by stress of acute ischemia, and 
raised catecholamine’s activates Na+/K+ATPase through β2 receptor. Previous 
use of non-selective beta blocker but not selective beta blocker use decrease 
ΔK. 
Sodium-proton exchanger also activates the enzyme Na+/K+ATPase. Insulin 
can activate this exchanger. But diabetic condition – Hyperinsulinemia which is 
indicated by increased HbA1c,reduces ΔK. Hence other factors like intracellular 
acidification and some neurohumoral controllers, including the renin-
angiotensin-aldosterone system may be involved in the activation of sodium 
proton exchanger when insulin resistance is present 
[52-55]
. 
It is thought that the potassium which is a intracellular cation leak outside when 
cardiac cells are damaged by ischemic attacks and leads to an rise in serum 
potassium  level during period of ischemia [thereby ΔK reduction]  similar to 
cardiac markers like creatine kinase MB,but it is observed that a higher peak 
CK level occurs  in patients with a greater ΔK and a lower potassium(K < 4.1) 
at the time of  admission however, the further analysis with Myocardial 
infarction demonstrated that ΔK was not significantly associated  with peak CK 
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level , thus it is concluded that delta potassium reflects the severity of  ischemic 
stress but not the extent of  myocardial injury
[56-58]
. 
Patients with severe ischemia has lower K level on admission and patients with 
lower serum potassium  level on admission was found to have a greater delta 
potassium
[59-60]
 .But the patients  who have with lower potassium level during 
ischemic attack did not have  low potassium concentration during stable period. 
All these indicate that lower potassium patients are more prone to larger 
potassium dip and it indicates admission disease severity 
[61-65]
. 
Low serum potassium concentration is seen in patients who presents earlier than 
those who came later. This Rapid recovery of serum potassium concentration 
has been found by serial blood sampling in patients with acute coronary 
syndrome 
[66].
The early recovery in serum potassium value inpatients presenting 
later after the onset of chest pain is most likely because of sympathetic 
withdrawal and this causes intracellular potassium to returning to the systemic 
circulation. The evidence for an sympathetic mediated mechanism of increasing 
serum potassium value with later admission to hospital was provided by 
findings in patients pre-treated with beta blockers 
[67]
.In this group the early 
decrease in serum potassium values and later increase were not seen probably 
because adrenergic activation of sodium-potassium-ATPase was blocked, 
reducing potassium shift intracellularly. This effect was seen mostly in unstable 
angina patients and was less marked in acute infarction where the early decrease 
in potassium and its later recovery were preserved, albeit with loss of 
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significance
[68-70]
. This shows that sympathetic responses to coronary syndromes 
are associated to the extent of myocardial injury hence larger in acute 
myocardial infarction, and it has the potential to overcome any effects caused 
by pre medications. 
 Increased serum potassium value is seen in diabetic patients with acute 
coronary syndromes and this shows the importance of insulin in potassium 
homeostasis 
[71]
. In Diabetes the early decrease in serum potassium 
concentration and its later recovery is not seen in unstable angina but occurs in 
acute myocardial infarction. In these regards, patients with diabetes mellitus 
behaves more likely patients treated with beta blockers, and  autonomic 
dysfunction being the most possible aetiology for the effects on potassium
[72]
. 
Again it is reasonable to propose that the increased sympathetic response to 
acute infarction overcome the effect of diabetes in modifying serum potassium 
values. 
Other  evidence for sympathetic mechanisms causing  early changes in serum 
potassium values in those  patients without diabetes  is provided by the inverse 
association between serum potassium within the first two hours of admission 
and various markers of  sympathetic  stress, including heart rate, hyper 
glycaemia, and bio markers of  cardiac injury
[73]
. These associations were seen 
only in those patients without diabetes. Those who have the marked  increase in 
heart rate, blood sugar, or creatine phosphokinase tended to have the larger 
reductions in serum potassium values that cannot modified  by sympathetic 
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nerve dysfunction or beta blockade. Insulin resistance may be an important 
factor in the early decrease in serum potassium in diabetes patients by 
decreasing the intracellular potassium shift early after the onset of symptoms. 
The findings of stable blood glucose values in n patients without diabetes during 
the early periods after the onset of chest pain, during which potassium 
concentrations varies rapidly, suggest that sympathetic mechanisms were more 
important than insulin in shifting potassium across the cell membrane 
[74-77]
. 
Sympathetic nerve dysfunction is a common finding in autonomic neuropathy, 
which can occur in forty percent of selected diabetic patients.A much greater 
percentage of patients may have minimal change of sympathetic functions as 
shown by myocardial radio labelled hydroxyephedrine uptake study using 
positron emission tomography. The association of autonomic nerve dysfunction 
in diabetes with a poor outcome and sudden cardiac death is well known fact. 
Prolongation of the QT interval, exaggeration of exertional ischemia, and 
dysregulation of sympathetically mediated cardiac blood flow are possible 
mechanisms. In diabetes increased serum potassium value in early period after 
the onset of symptoms in acute coronary syndromes is not thought to be harmful 
and may be beneficial in protecting against lethal ventricular arrhythmias 
[78]
. 
 Thus, while diabetes may be related with severe coronary syndromes, there are 
no evidence to shows it is associated with lethal ventricular arrhythmias 
[79]
. 
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TABLE 11: IMPACT OF DELTA POTASSIUM AND DISEASE 
SEVERITY 
 
 
TABLE 12: IMPACT OF POTASSIUM LEVEL AT ADMISSION AND 
DISEASE SEVERITY
 
The above tables show that when potassium is low at the time of admission, 
patients have long duration of stay and increased myocardial infarction. 
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METHODS AND MATERIALS: 
STUDY GROUP: 
Patients with acute coronary syndrome 
 1] STEMI 
2] UNSTABLE ANGINA  
3] NSTEMI  
STUDY DESIGN: CROSS SECTIONAL STUDY. 
MATERIALS: Detailed history, Physical examination, ECG, 2D 
Echocardiography, Chest x-ray, Complete Haemogram,RBS, Blood urea, Serum 
Creatinine, Serum potassium, cardiac enzyme CPK-MB,Urine Routine, Total 
Cholesterol, Triglyceride levels. 
PLACE OF STUDY: Govt. Kilpauk medical college hospital 
COLLABORATING DEPARTMENT: Department of Cardiology, KMCH 
and Department Of Biochemistry 
DURATION OF STUDY: 6 months 
CONSENT:After obtaining written informed consent 
CONFLICT OF INTEREST: Nil 
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METHODOLOGY:1)Potassium dip will be assessed by Δk-potassium at the 
time of discharge – potassium at the time of admission.  
2) Severity of ACS assessed by 
a) Duration of hospital stay 
 b) 2D echo  
c) Cardiac enzyme cpk-mb assay. 
INCLUSION CRITERIA:  
1. All patients > 35 yrs of age admitted with 1st  episode of acute coronary 
syndrome,  
EXCLUSION CRITERIA: 
1. Previous history of CAD. 
2. Patients with CKD. 
3. Patients on potassium controlling agents like ACE inhibitors, diuretics 
etc. 
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DATA COLLECTION: 
The data of each patient is collected in a specifically prepared proforma and 
includes  Demographic details, Proper history, Past medical history, Clinical 
Features, ECG, Echocardiography, Chest x-Ray, Rbs,serum potassium, CPK-
MB Level, Blood Urea, Serum Creatinine, Total Cholesterol and Triglyceride 
levels. 
STATISTICAL ANALYSIS  
Statistical analysis was done to identify significance and correlation 
betweenpotassium dip and severity of acute ischemic stress in patients with 
acute coronary syndrome. Statistical analysis was done using Statistics Products 
Services Solutions (SPSS 15) software. Univariate analysis was done with 
paired t test and Pearson product moment correlation coefficient. A chi squared 
test was used to analyze the probability of differences in frequency distributions 
between the groups and p<0.05 was taken to be statistically significant in all 
calculations. 
 
 
 
 
51 
 
RESULTS AND ANALYSIS 
TABLE:13.  AGE WISE CASE DISTRIBUTION 
 
Age in  years Frequency Percent 
 35-45 19 19.0 
 45-55 33 33.0 
 > 55 48 48.0 
 Total 100 100.0 
 
FIG 2.1 DISTRIBUTION OF CASES IN AGE GROUP 
 
 
The study group selected consist of three groups. Patient in age between 35 to 
45years, another in 46to 55 and final group more than 55. Most of the patient 
35-45 
19% 
45-55 
33% 
> 55 
48% 
AGE IN YEARS 
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are in final group. 48% were more than 55 years of age. 
TABLE 14 -DM IN STUDY GROUP 
 
DIABETES Frequency Percent 
Valid Yes 49 49.0 
 No 51 51.0 
 Total 100 100.0 
 
FIG: 2.2 SHOWINGDM IN STUDY GROUP 
 
49% of the patients with acute coronary syndrome in this study group had 
diabetes mellitus. 
 
Yes 
49% No 
51% 
DIABETES MELLITUS 
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TABLE: 15 SHT IN STUDY GROUP 
 
 
 
 
 
FIG 2:3 SHT IN STUDY GROUP 
 
52% of the patients with acute coronary syndrome in this study group have 
systemic hypertension. 
 
Yes 
52% 
No 
48% 
SHT 
                  
SHT Frequency Percent 
Valid Yes 52 52.0 
 No 48 48.0 
 Total 100 100.0 
54 
 
TABLE 16: DIAGNOSIS IN STUDY GROUP 
         GROUP Frequency Percent 
 
STEMI 
65 65.0 
 
NSETMI 
18 18.0 
UA 
 
17 17.0 
Total 
 
100 100.0 
 
FIG: 2.4.DIAGNOSIS IN ACS 
 
Patients with acute coronary syndromes were categorised in to three groups.  
Those with angina features, who have ST elevation in ECG, are diagnosed to 
have STEMI [ST elevation myocardial infarction]. Those with angina ECG 
STEMI 
65% 
NSTEMI 
18% 
UA 
17% 
DIAGNOSIS 
55 
 
changes [no ST elevation] and raised cardiac biomarkers are diagnosed as 
NSTEMI. Those with angina, with ECG changes without raised biomarkers are 
diagnosed to have unstable angina. 
Majority of the patient in the study groups has STEMI[65%], 18% HAS 
NSTEMI AND 17% has unstable angina. 
 
 
TABLE17. DURATION OF STAY 
 
 Frequency Percent 
Valid 5 days 31 31.0 
 6-7 46 46.0 
 > 7 23 23.0 
 Total 100 100.0 
 
Based on the duration of stay patients were divided into three groups. First 
group has duration of stay within 5 days and constitute 31% of the population in 
the study group. Those with duration of stay 6 and 7 days come under 2
nd
 group 
and constitute 46%. Finally those who stayed for more than 7 days come under 
3
rd
 group and constitute 23%. 
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FIG: 2.5. DURATION OF STAY OF PATIENTS 
 
TABLE.18.LEFT VENTRICULAR DYSFUNCTION 
 
 Frequency Percent 
Valid Normal 17 17.0 
 Mild 27 27.0 
 Moderate 42 42.0 
 Severe 14 14.0 
 Total 100 100.0 
 
 
Patients with normal left ventricular function based on 2D echocardiography 
constitute 17% in the study group. Patients with mild LV dysfunction [ejection 
fraction- 45 to 55%] constitute 27% of the study group. 42% of the study group 
5 days 
31% 
7-Jun 
46% 
> 7 
23% 
DURATION OF STAY 
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population has moderate LV dysfunction [EF- 30 to 45%]. Those with EF less 
than 30% have severe LV dysfunction and constitute 14% of the populations. 
 
FIG: 2.6 LV DYSFUNCTION IN STUDY GROUP 
 
 
TABLE.19. OUTCOME 
 
 Frequency Percent 
Valid Expired 10 10.0 
 Improved 90 90.0 
 Total 100 100.0 
Normal 
17% 
Mild 
27% Moderate 
42% 
Severe 
14% 
Left Ventricular Dysfunction 
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FIG: 2.7. OUTCOME IN STUDY GROUP 
 
Of the study groups 90% improved and discharged from the hospital. 10% 
expired. 
TABLE .20.INFLUENCE OF DIABETICS ON THE POTASSIUM AT 
THE OF ADMISSION 
 
 
Potassium - 
Admission Total 
 
 
P 
VALUE <= 4 > 4  
DM Yes Count 12 37 49  
 
0.401 
 No Count 9 42 51 
Total Count 
21 79 100 
Expired 
10% 
Improved 
90% 
OUTCOME 
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FIG:2.8 K AT ADMISSION AND DM 
 
 Of the 49% of the patients with diabetes mellitus only 12% has potassium less 
than 4 at admission  and remaining 37% has potassium above 4 meq/l. On the 
other hand 21% of the patients with no DM have potassium less than 4 and 
remaining 42% has potassium greater than 4. 
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TABLE 21.RELATION BETWEEN DURATION OF STAY AND 
POTASSIUM AT THE TIME OF ADMISSION 
 
 
Duration of stay 
 
Potassium - 
Admission Total 
 
P 
VALUE 
<= 4 > 4  
 
5 days 
Count 
6 25 31 
 
 
 
0.964 
6-7 
 
Count 
10 36 46 
> 7 
 
Count 
5 18 23 
Total Count 21 79 100 
 
Of the 31% of population with duration of stay within 5 days, only 6% has 
potassium less than 4 and remaining population has normal potassium. 10% of 
the population who stayed for 5 to 7 days has potassium less than 4. In Those 
who stayed for more than 7 days, only 5 patients have potassium less than 4.  
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FIG: 2.9 K AT ADMISSION AND DURATION OF STAY 
TABLE 22.CORRELATION BETWEEN POTASSIUM AT ADMISSION  
AND THE LV DYSFUNCTION. 
 
 
LV DYSFUNCTION 
 
Potassium - 
Admission Total 
<= 4 > 4  
NORMAL 
 
Count 6 11 17 
% within 
LVD 
35.3% 64.7% 100.0% 
MILD Count 5 22 27 
% within 
LVD 
18.5% 81.5% 100.0% 
MODERAT
E 
Count 6 36 42 
% within 
LVD 
14.3% 85.7% 100.0% 
SEVERE Count 4 10 14 
% within 
LVD 
28.6% 71.4% 100.0% 
35% of the patients with normal LV function have potassium dip. 19% of the 
patients with mild LV dysfunction have potassium less than 4. Of the 42 
0
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patients with moderate LV dysfunction only 14% has potassium dip. In patients 
with severe LV dysfunction only 28% has potassium less than 4 at the time of 
admission.  
 FIG: 3.1 K AT ADMISSION AND LV DYSFUNCTION 
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TABLE 23.DISTRIBUTION OF POTASSIUM AT ADMISSION IN 
VARIOUS GROUP OF ACS 
  
 
 
                DIAGNOSIS 
 
Potassium - 
Admission Total 
 
 
P 
VALUE <= 4 > 4  
STEMI 
 
Count 14 51 65  
 
 
 
 
0.96 
% within 
Diagnosis 
21.5% 78.5% 100.0% 
NSTEMI Count 1 17 18 
% within 
Diagnosis 
5.6% 94.4% 100.0% 
UA Count 6 11 17 
% within 
Diagnosis 
35.3% 64.7% 100.0% 
TOTAL Count 21 79 100 
% within 
Diagnosis 
21.0% 79.0% 100.0% 
 
The relationship between potassium at the time of admission and various ACS 
group is shown in the above table. It is clear from the above table that it has no 
significant correlation. 
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FIG: 3.2 K AT ADMISSION AND DIAGNOSIS 
 
 
Among 65 of the STEMI patients 14% has potassium less than 4 and remaining 
has normal LV function. In 18 patients with NSTEMI ONLY 6% had potassium 
less than 4. 35% of the unstable angina patients have potassium less than 4.  
Overall 21% has potassium less than 4. 
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TABLE 24.POTASSIUM VALUE AT ADMISSION AND OUTCOME 
 
 
                   OUTCOME 
 
 
Potassium - 
Admission Total 
 
 
P 
VALUE <= 4 > 4  
Expired 
 
 Count 
3 7 10 
 
 
 
 
 
 
0.351 
    
    
Improved      
 Count 18 72 90 
    
Total      
 Count 21 79 100  
     
      
 
 
FIG: 3.3 K AT ADMISSION AND OUTCOME 
 
33% of the expired patients have potassium dip. Among 90% of the improved 
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patients 18% patients has potassium less than 4. 
TABLE.25. DELTA POTASSIUM AGE WISE DISTRIBUTION 
  
 
 
       Age 
 
 
Delta potassium 
[meq/l] Total 
 
 
P 
VALUE >0.5 <0.5  
35-45  Count 12 7 19  
     
 
 
0.209 
    
45-55 
 
     
 Count 17 16 33 
    
>55      
 Count 34 14 48 
    
TOTAL      
 Count 63 37 100 
     
      
 
Delta potassium is defined as the difference in potassium at the time of 
discharge and admission value. 12 patients in the age 35 to 45 has delta 
potassium greater than 0.5. Among the 33 patients in the age group 45 to 55, 17 
has delta potassium greater than 0.5. 70% of the patients in the age group more 
than 55 have significant delta potassium. 
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FIG: 3.4.  DELTA K IN VARIOUS AGE GROUP 
 
FIG: 3.5. DELTA K AND SEX OF THE PATIENTS 
 
 
The above bar diagram shows the distribution of delta potassium and sex of the 
patients. Both have larger delta potassium. 
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TABLE 26.DELTA POTASSIUM AND SEX OF THE PATIENTS 
 
 
Sex 
 
 
Delta potassium 
        [meq/l] Total 
 
P value 
>0.5 <0.5  
Male 
 
 
 
Count 40 24 64  
 
 
 
 
0.89 
% within Sex 62.5% 37.5% 100.0% 
% within Potassium - 
Difference 
63.5% 64.9% 64.0% 
 
Female 
 
 
Count 23 13 36 
% within Sex 63.9% 36.1% 100.0% 
% within Potassium - 
Difference 
36.5% 35.1% 36.0% 
 
 
Total 
 
 
Count 63 37 100 
% within Sex 63.0% 37.0% 100.0% 
% within Potassium - 
Difference 100.0% 100.0% 100.0% 
 
 
62% of the male has delta potassium greater than 0.5. Among 36 females 23 has 
delta potassium which is 63%.  This shows there is no relation between sex and 
delta potassium. 
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TABLE 2.DELTA POTASSIUM IN DIABETIC AND NON DIABETIC 
GROUP 
 
  
 
 
Diabetes Mellitus 
 
Delta potassium 
       [meq/l] Total 
 
 
P 
VALUE >0.5 <0.5  
 Yes  Count 31 18 49  
   [63%] [37%]   
 
 
 
0.957 
      
       
 No  Count 32 19 51 
   [63%] [37%]  
       
Total  Count 63 37 100  
      
      
 
FIG: 3.6. DELTA K AND DM 
 
In both diabetics and non-diabetics 63% has delta potassium greater than 0.5 
and others has delta potassium less than 37%.  
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TABLE.28. DELTA POTASSIUM IN VARIOUS GROUPS 
 
          Diagnosis 
 
 
Delta potassium 
       [meq/l] Total 
 
 
p value 
>0.5 <0.5  
STEMI Count 47 18 65  
 
 
 
 
0.001 
% within 
Diagnosis 
72.3% 27.7% 100.0% 
NSTEMI 
 
Count 12 6 18 
% within 
Diagnosis 
66.7% 33.3% 100.0% 
UA Count 4 13 17 
% within 
Diagnosis 
23.5% 76.5% 100.0% 
TOTAL Count 63 37 100 
% within 
Diagnosis 
63.0% 37.0% 100.0% 
 
FIG: 3.7.DELTA POTASSIUM AND DIAGNOSIS 
 
From the above it is clear that delta potassium is greater in STEMI groups 
compared to others. 
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Among 65 of the STEMI patients 72% has delta potassium greater than0 .5 and 
remaining has low delta potassium. In 18 patients with NSTEMI 67% had 
potassium dip more than 0.5. 24% of the unstable angina patients have 
potassium dip of more than0.5 .Overall 63% has potassium dip. 
TABLE29. DELTA POTASSIUM AND DURATION OF STAY IN 
HOSPITAL 
 
 
 
Duration of stay 
 
Delta potassium 
 [meq/l] Total 
 
 
P 
VALU
E >0.5 <0.5  
 5 days  Count 6 25 31  
           
[19%] 
      
[81%] 
 
 
 
 
 
 
 
 
 
0.001 
       
 6-7  Count 35 11 46 
            
[76%] 
        
[24%] 
 
       
 > 7  Count 22 1 23 
            
[95%] 
        
[5%] 
 
       
Total  Count 63 37 100 
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Of the 31 patients with duration of stay within 5 days, only 19% has delta 
potassium greater than 0.5 and remaining population has normal potassium. But 
76%% of the population who stayed for 5 to 7 days has delta potassium greater 
than 0.5. In those who stayed for more than 7 days, 95% of patients has delta 
potassium more than 0.5%. 
 
FIG:3.8  DELTA POTASSIUM AND DURATION OF STAY 
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TABLE30. DELTA POTASSIUM AND  LV DYSFUNCTION. 
 
  
 
 
  LV Dysfunction 
 
Delta potassium 
  [meq/l] 
Total 
 
 
 
p value 
>0.5 <0.5 
 
A] 
Normal Count 2 
        
[12%] 
15 
       
[88%] 
17 
 
 
 
 
0.001 
 
B] 
Mild Count 9 
        
[50%] 
18 
       
[50%] 
27 
 
C] 
Moderate Count 39 
        
[93%] 
3 
          
[7%] 
42 
 
D] 
Severe Count 13 
        
[93%] 
1 
  [7%] 
14 
                             
Total 
Count 
63 37 100 
 
According to echocardiography findings of left ventricular function patients can 
be categorised into  
 Four groups   A] Those with normal left ventricular function B] Mild left 
ventricular dysfunction C] Moderate left ventricular dysfunction D] Severe left 
ventricular dysfunction From the above table it is clear patient with greater left 
ventricular dysfunction has larger delta potassium. 
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FIG: 3.9 DELTA K AND LV DYSFUNCTION 
 
Only 12% of the patients with normal LV function has Delta potassium greater 
than 0.5.On the other hand 50% of the patients with mild LV dysfunction have 
delta potassium more than 0.5. Of the 42 patients with moderate LV dysfunction 
93% has significant delta potassium. In patients with severe LV 
dysfunction93% has significant delta potassium. 
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TABLE31. RELATIONSHIP BETWEEN DELTA POTASSIUM AND 
POTASSIUM AT ADMISSION 
 
 
Potassium – Admission 
[mEq/L] 
 
Delta potassium 
       [meq/l] Total 
 
 
P value 
>0.5 <0.5  
 <= 4  Count 8 13 21  
   [38%] [62%]   
 
 
 
 
 
0.08 
    55 
[70%] 
24 
[30%] 
 
 > 4  Count   79 
      
       
      
Total  Count 63 37 100  
      
      
 
38% of the patients with potassium less than 4 have significant delta potassium 
and 70% of the patients with no potassium dip have significant delta potassium. 
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FIG: 4.1 DELTA K AND K+ AT ADMISSION 
 
 
38% of the patients with potassium less than 4 has significant delta potassium 
and 70% of the patients with no potassium dip have significant delta potassium. 
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DISCUSSION 
Ischemic heart disease is the important cause of morbidity and mortality in India 
as well as in other countries. Acute coronary syndrome is the medical 
emergency. Because of high prevalence of risk factors like smoking, 
hypertension, diabetes mellitus, alcoholism together with adverse life style 
changes it’s incidence is increasing day by day.  
Patients presenting with acute coronary syndromes commonly have 
hypokalaemia, which increases the risk of serious ventricular arrhythmias. 
Hypokalaemia can be viewed as an acute phase response to sympathetic 
activation, which stimulates membrane bound sodium-potassium- ATPase and 
drives potassium intracellularly.   
Prognosis in patients with acute coronary syndrome can be assessed by number 
of factors like associated failure signs, ejection fraction, raised biomarkers. Few 
studies have shown hypokalemia during episode of acute coronary syndrome 
can be associated with poor prognosis and adverse outcome.  
The present study asses the correlation between delta potassium and severity 
ischemic stress. The severity is assessed by three factors.  
1] Ejection fraction by 2D echo  
2] Duration of hospital stay.  
3] Rise in cardiac biomarkers. 
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Delta potassium is the difference between potassium at the time of discharge 
and at the time of admission. The study group consist of 100 patients admitted 
to cardiology with acute coronary syndrome.  
One study has shown the decreased potassium value at the time of admission 
has associated with large delta potassium and adverse outcome. So we analysed 
the potassium value at the time of admission with severity of ischemic stress.  
Majority of the patients admitted with ACS are more than 55 years of age, who 
constitute 48% of the study group.  Among the study group 64% are male and 
36% are female. 49% of the study group populations have diabetes mellitus.  
in the study group 65% had STEMI, 18% has NSTEMI and 17% has 
UNSTABLE ANGINA.   
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CORRELATION BETWEEN POTASSIUM VALUE AT THE OF 
ADMISSION AND SEVERITY OF ISCHEMIC STRESS 
 
In patients with diabetes mellitus only 25% has low potassium below 4 meq/l. 
while others has value above 4. This reflects in diabetes mellitus the initial 
decrease in potassium value is not seen. This may be due to autonomic 
dysfunction associated with diabetes mellitus. This is is supported by the study 
by27 Jarman 
PR, Kehley AM, Mather HM. Hyperkalaemia in diabetes:prevalence and 
associations. Postgrad Med J 1995;71:551–2. 
1] Among three groups of ACS patients in STEMI patients only 21% has low 
potassium value. In NSTEMI patients only 5% has absolute potassium value 
less than 4 at the time of admission. In UNSTABLE ANGINA 35% has low 
potassium value. This shows that there is no correlation between potassium 
value at the time of admission and enzyme activity.  
This may be due to difference in the time of admission which has impact on the 
potassium value at the time of admission. Only patients admitted earlier has low 
potassium value which gradually increases over time.  This is supported by the 
study- effect of diabetes on serum potassium concentrations inAcute 
coronary syndromes K Foo, N Sekhri, A Deaner, C Knight, A Suliman, K 
Ranjadayalan, A D Timmis.  
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2]The relation between duration of hospital stay is also not positive as shown 
below. 
GROUP A- those who stayed for less than 5 days- 19% has potassium less than 
4.  GROUP B- [those who stayed 5 to 7 days] 19% has low potassium value.  
GROUP C-[who stayed for more than 7 days] 21% has low potassium value.  
3] The relation between LV dysfunction and low potassium value at the time of 
admission is also not positive. In patients with normal LV dysfunction 35% has 
low potassium value, while 18% of patients with mild LV dysfunction has low 
potassium value. In patient with moderate LV dysfunction 18% has low 
potassium. Finally in severe lv dysfunction group 28% has lowpotassium value. 
This may be also due to difference in the time of admission as explained above.  
RELATION BETWEEN DELTA POTASSIUM AND SEVERITY OF 
ISCHEMIC STRESS 
 
A] Among 65 patients with STEMI 47 had delta potassium value more than 0.5 
which constitute 72%. In patients with NSTEMI 66% has significant delta 
potassium. But in UNSTABLE ANGINA group only 23% has delta potassium 
more than 0.5. This finding is consistent with the study. herlitz j, hjalmarson 
a,bengtsona: occurrence of hypokalemia in suspected acute myocardial 
infarction and its relation to clinical historyand clinical course. clincardiol 
1988, 11(10):678–682. 
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B] Delta potassium has also shown to be positively correlated with duration of 
stay in hospital as shown below.  
 1] Patient who stayed for 5 or less- 19% has significant delta potassium 
2] In the patient who stayed for 5 to 7- 76% has delta potassium more than 0.5 
3] In patients who stayed for more than 7 days- 96% has significant delta k.   
C] The relationship between delta potassium and LV dysfunction also correlate 
positively. In 17 patients with normal only 2 has delta potassium more than 2. In 
patients with mild LV dysfunction 33% has significant delta potassium. But 
92% of patients with moderate and 93% of patients with severe LV dysfunction 
has delta potassium more than 0.5. This is also supported by the study transient 
decrease in serum potassium levelduring ischemic attack of acute 
coronarysyndrome: hiroshi sekiyama1, tomohisa nagoshi1, kimiaki 
komukai1, masato matsushima2, daisuke katoh1, kazuo ogawa1,kosuke 
minai1, takayuki ogawa1 and michihiro yoshimura1. 
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CONCLUSION 
1] Prevalence of potassium dip is common among patients with acute coronary 
syndrome.  
2] Diabetic patients does not have significant delta potassium.  
3] Low potassium value at the time of admission [less than 4] was not found to 
correlate with disease severity in this study. 
4] Delta potassium was positively correlated with severity of ischemic stress in 
patients with ACS. 
5] Age, sex, diabetes, SHT, dyslipidaemia, smoking and alcoholism do not have 
major impact on delta potassium. 
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LIMITATION OF THE STUDY 
1] Sample size was small and further studies with larger sample are necessary.  
2] The study doesn’t analyse the time of onset of pain and admission time which 
may have an impact in the potassium value at the time of admission. 
3] The topic in general is new concept and few studies are available to compare 
the results. 
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ABBREVATIONS USED 
ACS- ACUTE CORONARY SYNDROME 
STEMI- ST ELEVATION MYOCARDIAL INFARCTION.  
NSTEMI- NON ST ELEVATION MYOCARDIAL INFARCTION 
UA- UNSTABLE ANGINA 
SHT- SYSTEMIC HYPERTENSION 
DM- DIABETES MELLITUS 
LVD- LEFT VENTRICULAR DYSFUNCTION 
AWMI- ANTERIOR WALL MYOCARDIAL INFARCTION 
IWMI- INFERIOR WALL MYOCARDIAL INFARCTION 
RVMI- RIGHT VENTRICULAR MYOCARDIAL INFARCTION 
CPK-MB- CREATININE PHOSPHOKINASE MB 
B-BLOCKER- BETA BLOCKER 
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CHD- CORONARY HEART DISEASE 
ACE- ANGOTENSION CONVERTING ENZYME 
PCI- PERCUTANEOUS CORONARY INTREVENTION 
ECG- ELECTROCARDIOGRAM 
HDL-HIGH DENSUTY LIPOPROTEIN 
LDL- LOW DENSITY LIPOPROTEIN 
SMC- SMOOTH MUSCLE CELL 
ECM- EXTRACELLULAR CELL MATRIX 
UFH- UNFRACTIONATED HEPARIN 
LMWH- LOW MOLECULAR WEIGHT HEPARIN 
COX- CYCLOXYGENASE. 
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PROFORMA 
 
NAME:       
AGE:   
SEX: 
ADDRESS:       Op No: 
  
D.O.A   D.O.D                          
DURATION OF HOSPITAL STAY 
HISTORY AND PAST HISTORY: 
 
 
SIGNS: 
 GENERAL 
 Built:    Pallor:   Icterus: 
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 Pedal oedema:             Temp:     Hydration: 
 Clubbing:   PR:                               BP: 
          
CVS: 
RS : 
PER ABDOMEN: 
CNS: 
INVESTIGATIONS 
      Complete haemogram: HB, TC,DC,ESR 
RBS. 
Δk-(potassium at the time of discharge – potassium at the time of admission) 
Urea 
Creatinine 
       Serum CPK-MB . 
      Total Cholesterol 
      Triglyceride level 
Urine:  
100 
 
     Sugar 
     Albumin  
     Deposits  
ECG 
Echocardiography 
Chest X-Ray 
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